Business, energy, technology, markets and global industry news from Business News Today

Viking Global Investors

PharmaDeviceNews Viking Global Investors
Editorial infographic showing TriGemX Bio’s planned $246 million SPAC transaction to support Phase 3 elismetrep trials, featuring laboratory imagery, clinical trial documents, financial charts, and key development milestones.
Pharma & Biotech

TriGemX Bio agrees $246m SPAC deal to advance elismetrep migraine trials

TriGemX Bio plans a $246 million SPAC transaction to fund Phase 3 elismetrep trials. Clinical results and deal completion will determine its future.

Read More
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More